![]() |
Volumn 22, Issue 9 II, 2002, Pages
|
Dose conversion from recombinant human erythropoietin to darbepoetin alfa: Recommendations from clinical studies
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTINEOPLASTIC AGENT;
HEMOGLOBIN;
NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;
RECOMBINANT ERYTHROPOIETIN;
SIALIC ACID;
ANTIANEMIC AGENT;
DRUG DERIVATIVE;
ERYTHROPOIETIN;
ANEMIA;
BLOOD TRANSFUSION;
CANCER CHEMOTHERAPY;
CHRONIC KIDNEY DISEASE;
CLINICAL TRIAL;
DOSE CALCULATION;
DRUG CLEARANCE;
DRUG EFFICACY;
DRUG HALF LIFE;
DRUG POTENCY;
HUMAN;
NONHUMAN;
REVIEW;
SOLID TUMOR;
CHRONIC KIDNEY FAILURE;
COMPARATIVE STUDY;
DRUG ADMINISTRATION;
DRUG LABELING;
INTRAVENOUS DRUG ADMINISTRATION;
METABOLISM;
NEOPLASM;
PHARMACOKINETICS;
ANEMIA;
CLINICAL TRIALS;
DRUG ADMINISTRATION SCHEDULE;
DRUG LABELING;
EPOETIN ALFA;
ERYTHROPOIETIN;
HEMATINICS;
HUMANS;
INJECTIONS, INTRAVENOUS;
KIDNEY FAILURE, CHRONIC;
NEOPLASMS;
THERAPEUTIC EQUIVALENCY;
|
EID: 0036367982
PISSN: 02770008
EISSN: None
Source Type: Journal
DOI: 10.1592/phco.22.14.160s.33398 Document Type: Review |
Times cited : (69)
|
References (14)
|